Unknown

Dataset Information

0

LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.


ABSTRACT: Deficiency in DNA double-strand break (DSB) repair mechanisms has been widely exploited for the treatment of different malignances, including homologous recombination (HR)-deficient breast and ovarian cancers. Here we demonstrate that diffuse large B cell lymphomas (DLBCLs) expressing LMO2 protein are functionally deficient in HR-mediated DSB repair. Mechanistically, LMO2 inhibits BRCA1 recruitment to DSBs by interacting with 53BP1 during repair. Similar to BRCA1-deficient cells, LMO2-positive DLBCLs and T cell acute lymphoblastic leukemia (T-ALL) cells exhibit a high sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. Furthermore, chemotherapy and PARP inhibitors synergize to inhibit the growth of LMO2-positive tumors. Together, our results reveal that LMO2 expression predicts HR deficiency and the potential therapeutic use of PARP inhibitors in DLBCL and T-ALL.

SUBMITTER: Parvin S 

PROVIDER: S-EPMC6752209 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7010753 | BioStudies
2015-01-01 | S-EPMC4671316 | BioStudies
2012-01-01 | S-EPMC3771348 | BioStudies
2012-01-01 | S-EPMC3427093 | BioStudies
2016-01-01 | S-EPMC5090703 | BioStudies
2016-01-01 | S-EPMC4858320 | BioStudies
2020-01-01 | S-EPMC7429965 | BioStudies
2017-01-01 | S-EPMC5519258 | BioStudies
2016-01-01 | S-EPMC4747838 | BioStudies
2010-01-01 | S-EPMC2913123 | BioStudies